GNPX News and Press, Genprex Inc. From 08/15/22

Gainers: Viridian Therapeutics VRDN +45% . TherapeuticsMD TXMD +21% . Unity Biotechnology UBX +21% . Brainstorm Cell Therapeutics BCLI +12% . Genprex GNPX +10% . Losers: IDEAYA Biosciences IDYA -33% . Apexigen ( APGN ) -15%...

Genprex ( NASDAQ: GNPX ) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-st...

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer PR Newswire Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its manufacturing leadership will present sessions on cutting-edge topics in lipid-based nanoparticle delivery systems at...

Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit PR Newswire Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems AUSTIN, Texas , July 13, 2022 /PRNew...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting at two upcoming investor conferences: the LD Micro Invitational and the BIO International Convention. The company’s p...

Genprex to Present at Upcoming June Investor Conferences PR Newswire Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN , Texas , June 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Compan...

If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its CEO and President Rodney Varner will be providing a virtual overview of Genprex’s pioneering gen...

Genprex to Present at Upcoming Investor Conference in May 2022 PR Newswire Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "C...